[A18-71] Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V

Last updated 01.02.2019

Project no.:
A18-71

Commission:
Commission awarded on 29.10.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Head and nerves

Indication/Intervention:

Prophylaxis of migraine

Result of dossier assessment:

Patients who do not respond to other drug classes, or do not tolerate them, or for whom these are unsuitable: indication of considerable added benefit. Patients with other treatment options: added benefit not proven.

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

01.02.2019

Erenumab in migraine: indication of considerable added benefit for certain patients

Successful prophylaxis if other drug treatment options have been exhausted

Current document

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2019-09-19 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.